Silo Pharma | Investor Presentation Deck | 24 slides

Silo Pharma · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

24
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a molecular structure graphic to reinforce the pharmaceutical theme.establish_context
Open slide detailBeat · Problem
04
summarize
Open slide detailBeat · Problem
05
The slide maps specific university/corporate partners to their respective drug development programs (SP-26, SPU-16, SPU-21, SPC-14, SPC-15, Generic psilocybin).other
Open slide detailBeat · Problem
06
plan_implementation
07
The slide lists specific patent numbers and filing dates to establish credibility.other
08
transition
09
The slide outlines the market opportunity, technology, and specific applications for the SP-26 program.present_solution
Open slide detailBeat · Solution
10
Slide 10 of a pitch deck for Silo Pharma.establish_context
Open slide detailBeat · Solution
11
The slide outlines a specific asset (SPU-21) under a license agreement with UMB, detailing market size, technical mechanism, and research status.present_solution
Open slide detailBeat · Solution
12
Slide 12 of a pitch deck.establish_context
Open slide detailBeat · SolutionLoop · Voice Of Customer
13
The slide outlines a specific pharmaceutical asset (SPC-15) and its market context.present_solution
Open slide detailBeat · SolutionLoop · Voice Of Customer
14
The slide outlines a specific research partnership and its scope.present_solution
Open slide detailBeat · Solution
15
transition
Open slide detailBeat · Team
16
other
Open slide detailBeat · Team
17
other
Open slide detailBeat · Team
18
other
Open slide detailBeat · Team
19
This is a placeholder or section divider slide.summarize
20
Slide 20 of the deck.summarize
21
plan_implementation
Open slide detailLoop · Quick Win Big Bet
22
The table highlights SiloPharma's unique 505(b)(2) regulatory pathway compared to peers.compare_peers
Open slide detailBeat · FinancialsLoop · Quick Win Big Bet
23
summarize
Open slide detailBeat · FinancialsLoop · Quick Win Big Bet
24
state_next_steps